Skip to content

Effects of an Interactive ICT-Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer

PhONEME - PartipatOn Ehealth MobilE. Effects of an Interactive Information and Communications Technology (ICT) Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02477137
Acronym
PhONEME
Enrollment
150
Registered
2015-06-22
Start date
2015-07-20
Completion date
2018-03-07
Last updated
2018-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Prostate Cancer, Nursing, Health Literacy, Quality of Life, Radiotherapy, Oncology Nursing, Self Care, Symptom Management, Participatory Care, Person-centered Care, Information and Communication Technology, Patient-reported symptoms, Mobile device

Brief summary

The purpose of this study is to evaluate the effects of an interactive ICT-platform for use in a smartphone or tablet in patients treated with radiotherapy for prostate cancer. The hypothesis is that clinical management will be improved and costs reduced and safe and participatory care promoted, when patients report symptoms in an application which provides self-care advice and instant access to professionals.

Interventions

Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.

Sponsors

Karolinska University Hospital
CollaboratorOTHER
Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of prostate cancer without metastases or spread to the lymph nodes, * will receive radiation therapy for at least five (5) weeks, * literacy in the Swedish language

Exclusion criteria

* Patients who need an interpreter at the doctor's visit * Patients who have a known severe cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Questionnaire Sense of Coherence Scale (KASAM)up to 3 months after completion of radiotherapy treatmentTo evaluate self-reported data in terms of Sense of Coherence
Questionnaire Individualized Care Scale (ICS)up to 3 months after completion of radiotherapy treatmentTo evaluate self-reported data in terms of individualized care as measured by the ICS
Questionnaire Scale for Functional Health Literacy (S-FHL - Swedish version)up to 3 months after completion of radiotherapy treatmentTo evaluate self-reported data in terms of understanding and communicating health
Scale for Communicative and Critical Health Literacy (S-C & C HL - Swedish version)up to 3 months after completion of radiotherapy treatmentTo evaluate self-reported data in terms of health literacy
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)up to 3 months after completion of radiotherapy treatmentTo evaluate self-reported data in terms of health related quality of life
EORTC Prostate-specific module (QLQ-PR25) Questionnaireup to 3 months after completion of radiotherapy treatmentTo evaluate self-reported data in terms of symptom prevalence, characteristics and distress related to prostate cancer

Secondary

MeasureTime frame
Health care costsup to 3 months after completion of radiotherapy treatment

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026